Author: ALLISON GATLIN
Source
Agios stock yo-yoed Wednesday after the company’s pill outperformed in a study of thalassemia patients.
The post Agios Stock Whipsaws As It Looks To Rival Crispr, Vertex In A Key Market appeared first on Investor’s Business Daily.